Last reviewed · How we verify

NCT05332756

Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)

Recruiting now Last updated 19 December 2024
What this trial tests

trial testing Conservative management in Moyamoya Disease in 400 participants. Currently enrolling.

Timeline
1 May 2022
Primary endpoint
30 November 2026
31 December 2026

Quick facts

Lead sponsorBeijing Tiantan Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment400
Start date1 May 2022
Primary completion30 November 2026
Estimated completion31 December 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Tiantan Hospital

Who can join

Adults 2 to 60, any sex, with Moyamoya Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the long-term outcomes of conservative management in patients with moyamoya disease and their first-degree relatives, and provide potential pathogenesis of moyamoya disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Medical Management of Adult Moyamoya Disease: A Review and Relevant Cases With Ischemic Events.
    Bang OY, Fujimura M. · · 2025 · cited 2× · PMID 39916450 · DOI 10.5853/jos.2024.04273

Verify or expand the search:

Other trials of Conservative management

Trials testing the same drug.

Other recruiting trials for Moyamoya Disease

Currently open trials in the same condition.

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05332756.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing